AZD1775
1 clinical trial
2 abstracts
1 indication
Indication
Uterine CancerAbstract
A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).Org: Moffit Cancer Center,
Clinical trial
A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine CarcinosarcomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Abstract
A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.Org: University of California San Francisco, Vanderbilt University Medical Center, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Robert H. Lurie Comprehensive Cancer Center of Northwestern University,